Trademark Search in Canada

GAMIFANT

View On IC.GC.CA

REGISTERED

on 21 Aug 2019

Last Applicant/ Owned by

SWEDISH ORPHAN BIOVITRUM AG

14 ch. des Aulx1228 Plan-les-OuatesGeneva

Serial Number

1843975 filed on 21^st Jun 2017

Registration Number

TMA1050415 registered on 21^st Aug 2019

Registration expiry Date

21^st Aug 2029

Correspondent Address

OSLER, HOSKIN & HARCOURT LLP

SUITE 6200, P.O. BOX 501 FIRST CANADIAN PLACETORONTO

ONTARIO

M5X1B8

GAMIFANT

Trademark usage description

biochemicals, namely, polypeptides, superantigens, biomarkers and antibodies for medical and scientific research; diagnostic agents, namely antigens, Read More

Classification Information

Class [001]
Biochemicals, namely, polypeptides, superantigens, biomarkers and antibodies for medical and scientific research; diagnostic agents, namely antigens, for medical and scientific research for medical and scientific research; diagnostic biomarker reagent for biomarker reagents for medical and scientific research; diagnostic test kits consisting primarily of biomarkers for medical and scientific research; biochemical test kits consisting of assays and reagents for medical and scientific research purposes

Classification kind code

Class [005]
Pharmaceutical and biological preparations for the treatment of cancer, immunologic diseases, namely autoimmune diseases and immunologic deficiency syndromes, organ and bone marrow transplant rejection conditions, inflammatory diseases, namely inflammatory bowel diseases, inflammatory connective tissue diseases, inflammatory muscle diseases and disorders and arthritis; pharmaceutical and biological preparations based on polypeptides, superantigens, biomarkers and antibodies for the treatment of cancer, immunologic diseases, namely autoimmune diseases and immunologic deficiency syndromes, organ and bone marrow transplant rejection conditions, inflammatory diseases, namely inflammatory bowel diseases, inflammatory connective tissue diseases, inflammatory muscle diseases and disorders and arthritis; immunotherapies for stimulating the immune response; pharmaceutical and biological preparations for use in the diagnosis, prevention, management and treatment of immunologic diseases, namely, autoimmune diseases, immunologic deficiency syndromes, organ and bone marrow transplant rejection conditions, inflammatory diseases, namely inflammatory bowel diseases, inflammatory connective tissue diseases, inflammatory muscle diseases and disorders and arthritis, oncological, viral diseases, namely herpes, hepatitis, Acquired Immune Deficiency Syndrome (AIDS), infectious diseases, namely, respiratory infections, eye infections, topical infections, neurological diseases and disorders, namely Alzheimer's, Huntington's Disease, cerebral palsy, brain injury, spinal cord injury, seizure disorders, musculoskeletal diseases, namely connective tissue diseases, bone diseases, spinal diseases, back pain, fractures, sprains and cartilage injuries, respiratory, and dermatological diseases, namely dermatitis, skin pigmentation diseases; therapeutic and diagnostic agents, namely antigens, for medical and scientific research, preparations and substances for use in therapies for immunologic diseases, namely autoimmune diseases and immunologic deficiency syndromes, organ and bone marrow transplant rejection conditions, inflammatory diseases, namely inflammatory bowel diseases, inflammatory connective tissue diseases, inflammatory muscle diseases and disorders and arthritis, oncological, viral diseases, namely herpes, hepatitis, Acquired Immune Deficiency Syndrome (AIDS), infectious diseases, namely, respiratory infections, eye infections, topical infections, neurological diseases and disorders, namely Alzheimer's, Huntington's Disease, cerebral palsy, brain injury, spinal cord injury and seizure disorders, musculoskeletal diseases, namely connective tissue diseases, bone diseases, spinal diseases, back pain, fractures, sprains and cartilage injuries, respiratory, and dermatological diseases, namely dermatitis, skin pigmentation diseases; biochemical preparations for medical purposes, polypeptides, antibodies, biomarkers and superantigens for use in diagnoses and therapies for immunologic diseases, namely, autoimmune diseases, immunologic deficiency syndromes, organ and bone marrow transplant rejection conditions, inflammatory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases, inflammatory muscle diseases and disorders, arthritis, oncological, viral diseases, namely, herpes, hepatitis, Acquired Immune Deficiency Syndrome (AIDS), infectious diseases, namely, respiratory infections, eye infections, topical infections, neurological diseases and disorders, namely, Alzheimer's, Huntington's Disease, cerebral palsy, brain injury, spinal cord injury, seizure disorders, musculoskeletal diseases, namely, connective tissue diseases, bone diseases, spinal diseases, back pain, fractures, sprains, cartilage injuries, respiratory, and dermatological diseases, namely, dermatitis, skin pigmentation diseases; engineered cell therapies, namely engineered T cells, immune cells and antibodies, for medical purposes; diagnostic biomarker reagents for medical purposes; diagnostic test kits consisting of biomarkers for medical purposes; biochemical test kits comprised of assays and reagents for medical, diagnostic and therapeutic purposes.

Classification kind code

Mark Details

Serial Number

1843975

Mark Type

Trademark

Legal History

Action Taken	Status
Submitted for opposition 190 on 7^th Aug 2019	Registration Pending
Submitted for opposition 42 on 15^th May 2019	Advertised
Submitted for opposition 26 on 25^th Apr 2019	Approved
Submitted for opposition 27 on 8^th Mar 2019	Approval Notice Sent
Submitted for opposition 12 on 15^th Jan 2019	Extension of Time
Submitted for opposition 22 on 8^th Jun 2018	Search Recorded
Submitted for opposition 20 on 8^th Jun 2018	Examiner's First Report
Submitted for opposition 31 on 29^th Jun 2017	Formalized
Submitted for opposition 1 on 22^nd Jun 2017	Created
Submitted for opposition 30 on 21^st Jun 2017	Filed